As Emcure Pharma debuted on the NSE with a 31% premium, well-known investor from Shark Tank India and Emcure Pharmaceuticals executive director Namita Thapar is witnessing incredible returns on her money. Originally ₹2.19 crore, Thapar’s initial investment in the company has now risen to almost ₹671 crore following the IPO.
Starting on the NSE at ₹1,325.05 per share, Emcure Pharmaceuticals demonstrated a 31.45% premium over its issue price of ₹1,008. With 67.87 times of subscription, the IPO—valued at ₹1,522.03 crore—created strong interest from investors. Seven times was the subscription for the retail book; the non-institutional investor (NII) part was subscribed 48 times; the qualified institutional buyers (QIBs) section was subscribed an incredible 195 times. Selling 12.68 lakh shares during the IPO’s offer-for- sale component brought Thapar roughly ₹127.87 crore. Reflecting a stunning 38,200% return based on the listing price, her remaining 50.71 lakh shares now value her investment at ₹671 crore.
The IPO included a fresh issue of 0.79 crore shares valued ₹800 crore and an offer for sale of 1.14 crore shares valued ₹1,252.03 crore. Each share’s price range was determined upon as ₹960 to ₹1,008. Before the IPO Emcure had attracted ₹582.6 crore from anchor investors including Goldman Sachs, Morgan Stanley, and the Abu Dhabi Investment Authority.
Managed by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited Emcure Pharmaceuticals, Under Link Intime India Private Limited, the registrar, achieved a fantastic market debut. Originating in India, the company focuses in designing, producing, and global marketing pharmaceutical products across multiple therapeutic domains. Emcure runs 13 manufacturing locations all throughout India and produces injectables, biotherapeutics, and orals among other dosage forms.
Strong investor interest was drawn to Emcure’s IPO; QIBs spearheading the charge subscribed 92.94 times their allowed quota. Non-institutional investors purchased 42.57 times the allotted amount while staff members showed clear interest and submitted bids 7.9 times their allocated quota. Retail investors bought shares meant for them 6.33 times over. On July 8, share allocation was decided upon; on July 10 Emcure Pharma shares were listed on the BSE and NSE.
Emcure Pharmaceuticals is somewhat well-known internationally having products in more than 70 countries. The company’s range of products consists in oral solids, oral liquids, injectables, and advanced active pharmaceutical ingredients (APIs) comprising cytotoxic goods, iron molecules, and chiral molecules. Notwithstanding market volatility, Emcure’s successful IPO reveals tremendous investor confidence in the company’s expansion prospects and pharmaceutical industry posture.
Notice: Business Today provides stock market news for informational only purposes; it should not be utilized as financial guidance. Readers should consult a certified financial adviser before choosing any investment.
